SUMMARY Suppositories of sulphapyridine, 5-aminosalicylic acid, and placebo were used in 45 patients with idiopathic proctitis to determine the active part of sulphasalazine. Each patient used one of the suppositories twice daily for four weeks in a double-blind controlled trial. Complete clinical remission with normal rectal mucosa on sigmoidoscopy occurred in 60% of patients given 5-aminosalicylic acid, but in only 13% and 27% of those given sulphapyridine and placebo respectively. Twelve patients were included twice. tn eight of these patients 5-aminosalicylic acid was given one time and sulphapyridine (two patients) or placebo (six patients) another time. Clinical remission occurred in each patient with 5-aminosalicylic acid, but in only one patient during other therapy. The results suggest that 5-aminosalicylic acid is the active therapeutic moiety of sulphasalazine.
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Salicylazosulphapyridine (Salazopyrin, sulphasalazine, SASP) is widely used in the treatment of ulcerative colitis and Crohn's disease. Several controlled trials have established its value in mild and moderately active colitis ' and in maintenance therapy to prevent recurrence of the disease3 4. Its value in Crohn's disease has not yet been established.
SASP is composed of sulphapyridine (SP) in azo linkage with 5-aminosalicylic acid (5-ASA). After an oral dose of SASP in man, only a small fraction is absorbed in the small bowel. Most of the drug reaches the colon and is almost completely split at the diazo bond by bacterial azo-reductases into SP and 5-ASA.5 6 SP is then mostly absorbed and partially metabolised in the liver (acetylation and glucuronidation) before excretion in the urine. Most of the 5-ASA moiety can be recovered in the faeces and only a small portion is found in the urine as the acetylated form.7
The mode of action of SASP remains unknown.
As SASP is particularly effective in the treatment of *Address for reprint requests: P A M van Hees, MD, Department of Medicine, Division of Gastroenterology, St. Radboud 'Hospital, Geert Grooteplein Z16, Nijmegen, The Netherlands.
Received for publication 1 October 1979 inflammatory disease of the large bowel, it has been suggested that one of the metabolites, rather than SASP itself, may be responsible for the drug's activity at the site of breakdown. The present study was devised to determine the active therapeutic moiety of SASP. Since SP and 5-ASA are almost completely absorbed in the small intestine5 it was not possible to study the effect of these compounds after oral administration in patients with inflammatory bowel disease. Therefore we investigated the effect of rectally administered SP, 5-ASA, and a placebo in patients with idiopathic proctitis. Rectal administration of SASP was felt to be inappropriate because the compound is split in the rectum.
Methods

PATIENTS
Idiopathic proctitis is defined as an inflammatory condition of the rectal mucosa of unknown cause which on sigmoidoscopic examination is limited to the rectum, above which the mucosa appears normal; the colon also appears normal on barium enema x-ray examination. Forty-five outpatients who fulfilled these criteria were included in the trial. The study was carried out in accordance with the 632 The results were analysed with the aid of the yand sign test. Table 2 shows the change in patients' symptoms and Table 3 the change in the sigmoidoscopic appearances after treatment for four weeks. All patients who had a normal rectal mucosa at sigmoidoscopy were also free of symptoms, so that the effect of therapy in these patients could be rated as successful (Table 4) . The proportion of patients with a complete clinical remission in the 5-ASA group was much higher than in the SP and placebo groups (p 0-020). proctitis. These patients could therefore serve as their own controls. These results indicate that 5-ASA therapy is superior to placebo. Of six patients treated with both 5-ASA and placebo, six had a complete clinical remission during 5-ASA and none during placebo (sign test: P<0 05) . In all the patients in the SP and 5-ASA group, SP and 5-ASA was demonstrable in the urine, respectively. After four weeks' therapy, SP excretion in 24-hour urine ranged from 47 to 181 mg (mean SD; 110± 55 mg). In patients on 5-ASA therapy, the 5-ASA excretion ranged from 28 to 204 mg (mean ± SD; 93 + 59 mg). No SASP, SP, or 5-ASA was demonstrable in the urine of the patients in the placebo group.
Results
Discussion
The results of this study suggest that 5-ASA is the therapeutically active moiety of SASP. SP was no more effective than a placebo.
Idiopathic proctitis is generally considered to be the same disease as ulcerative colitis, which is localised to the rectum.1'-' After oral administration SASP is almost completely split into SP and 5-ASA by colonic bacteria. 5-ASA is largely recovered in the stools.7 It may therefore be assumed that in ulcerative colitis, too, SASP is active because of a local effect of 5-ASA.
Our findings accord with those of Azad Khan et al.16 These authors investigated the effect of locally administered SASP, SP, 
